Form 8-K - Current report:
SEC Accession No. 0001636282-24-000105
Filing Date
2024-11-18
Accepted
2024-11-18 16:01:34
Documents
13
Period of Report
2024-11-18
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K syre-20241118.htm   iXBRL 8-K 62352
  Complete submission text file 0001636282-24-000105.txt   197758

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20241118.xsd EX-101.SCH 1777
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20241118_lab.xml EX-101.LAB 23727
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20241118_pre.xml EX-101.PRE 13584
15 EXTRACTED XBRL INSTANCE DOCUMENT syre-20241118_htm.xml XML 2927
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 241471410
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)